Research Article

The Effectiveness of Saireito, a Traditional Japanese Herbal Medicine, in Reducing Postoperative Edema after Acquired Ptosis Surgery: A Prospective Controlled Trial

Naoki Morimoto,1 Natsuko Kakudo,1 Toshihito Mitsui,1 Atsuyuki Kuro,1 Yuko Ueda,1 Masakatsu Hihara,1 Yoshihito Tanaka,2 Yujiro Ozaki,2 Kenji Suzuki,2 and Kenji Kusumoto1

1Department of Plastic and Reconstructive Surgery, Kansai Medical University, Japan
2Department of Plastic and Reconstructive Surgery, Kansai Medical University Medical Center, Japan

Correspondence should be addressed to Naoki Morimoto; morimotn@hirakata.kmu.ac.jp

Received 11 December 2017; Revised 23 April 2018; Accepted 4 June 2018; Published 27 June 2018

Academic Editor: Louise Bennett

Background. Persistent edema is a common complication after the surgical treatment of blepharoptosis; however, no objective methods have been established for evaluating or treating this condition. We focused on the Japanese herbal medicine, Saireito, and evaluated its efficacy in reducing postoperative edema.

Methods. This was a prospective, nonrandomized, and controlled study. We evaluated the incidence of postoperative edema in a Control group using a subjective patient-assessed visual analog scales (VASs) to assess swelling, pain, itching, and local warmth and an objective surgeon-assessed VAS to evaluate swelling. Swelling was also assessed by an objective computer-based analysis of digital images. These methods were used to evaluate the effects of Saireito (8.1 g/day) for 8 weeks.

Results. A total of 49 patients and 80 eyelids were enrolled. Twenty-nine patients and 48 eyelids were assigned to the Control group, and 20 patients and 32 eyelids were assigned to the Saireito group. Our analysis of the Control group indicated that postoperative edema persisted for up to 8 weeks. On the other hand, the postoperative edema in the Saireito group was mostly eliminated at 8 weeks. The computer-based analysis of digital images showed that the edema tended to be reduced in the Saireito group compared with the Control group.

Conclusion. Saireito might be effective for reducing postoperative edema after blepharoptosis surgery and almost completely eliminated it at 8 weeks after surgery. This study was a preliminary and nonrandomized study; therefore, the randomized and placebo-controlled study will be needed in the next step.

1. Introduction

Mechanical blepharoptosis, such as aponeurotic ptosis and/or dermatochalasis of the upper eyelids, is the most common cause of acquired ptosis [1]. Complications after ptosis surgery, including major complications such as retrobulbar hematoma and ectropion, are rare. On the other hand, minor complications, including subcutaneous hematoma, eyelid malposition, scarring, and persistent edema, remain very common [2, 3]. Edema, which often continues for more than 4 weeks in the clinical setting, causes suffering and sometimes results in eyelid malposition, scarring, or the recurrence of ptosis [2, 3]. Edema within one week is treated or prevented by cooling, compression, or the administration of steroids; however, there are no well-established techniques for the management of persistent edema.

The Japanese herbal medicine Saireito is a combination of two herbal medicines (Shosaikoto and Goreisan) that is used to treat inflammatory diseases as well as autoimmune diseases such as rheumatoid arthritis, cirrhosis, and nephrotic syndrome [4–7]. Saireito has also been demonstrated to be effective in treating edema after total hip arthroplasty and lymphedema after radiotherapy [8, 9]. In addition, it has been reported to have antifibrotic properties; thus, it is useful for the treatment of fibrosis or hypertrophic scars [10, 11].

In the present study, we investigated the incidence of postoperative edema at up to eight weeks after the surgical
treatment of ptosis and evaluated the efficacy of Saireito in reducing postoperative edema.

2. Methods

2.1. Study Design. Each patient in this multicenter, prospective, nonrandomized, controlled study underwent acquired ptosis surgery, which involved the incision of the eyelid fold. This study was performed at Kansai Medical University Hospital and Kansai Medical University Medical Center. All operations performed at the two locations were performed by specialists in plastic and reconstructive surgery. During the study period, there were no established methods for evaluating edema after eyelid ptosis surgery. Thus, in the present study, we used a novel method to evaluate postoperative edema in 30 patients who underwent ptosis surgery but who did not receive Saireito (Control group). Then, after confirming that our evaluation method was reasonable, we evaluated postoperative edema in 30 patients who underwent ptosis surgery and who were treated with Saireito (Saireito group).

The protocol of the Control group study was approved by the institutional review boards of Kansai Medical University Hospital (permit number: H130938) and Kansai Medical University Medical Center (permit number: 25-7). The protocol of the Saireito group study was approved by the institutional review board of Kansai Medical University Hospital (permit number: H140407) and Kansai Medical University Medical Center (permit number: 26-22). The Saireito group study was registered in the UMIN Clinical Trials Registry (number: UMIN000016258). The Control group study was not registered in the UMIN Clinical Trials Registry because it was an observational study without any intervention; thus, at the time of the study, registration was not required according to the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects.

2.2. Patients. Patients who met the eligibility criteria were recruited for the Control group from September 2013 to September 2014 (Table 1). The patients in the Saireito group were recruited from December 2014 to March 2016; the same eligibility criteria were applied. Patients who received herbal medicine within 2 weeks before surgery were excluded from the study. The target sample size of each group was 30. The baseline data that were collected before enrollment included age, sex, comorbidities, and history of ptosis surgery.

2.3. Interventions. Under local anesthesia, the skin along the patient’s eyelid fold was incised and the redundant eyelid skin was removed according to the degree of dermatochalasis. The levator aponeurosis was dissected from the tarsus and advanced or resected to the extent that was required. The aponeurosis and skin were sutured using 6-0 or 7-0 nylon. In the Saireito group, Saireito (EK-114, Kracie Pharma, Ltd., Tokyo, Japan) was administered orally as a solution immediately before meals at a dose of 2.7 g 3 times daily (8.1 g/day), for 8 weeks, starting just after surgery. According to the manufacturer’s information, Saireito is a water extract of herbal powder; 8.1 g of Saireito is prepared from a decoction of the following 12 medicinal herbs: Bupleurum root (7.0 g), Pinellia tuber (5.0 g), Alisma rhizome (6.0 g), Scutellaria root (3.0 g), Ginseng radix (3.0 g), Jujube fruit (3.0 g), Poria sclerotium (4.05 g), Polyporus sclerotium (4.5 g), Atractylodes rhizome (4.5 g), Cinnamon bark (3.0 g), Glycyrrhiza root (2.0 g), and Ginger rhizome (1.0 g). Saireito is approved as a herbal medicine under the Japanese National Health Insurance Program and is indicated for the relief of edema [5–10].

2.4. The Evaluation of Postoperative Edema after Blepharoptosis Surgery. The subjective symptoms of postoperative edema, including swelling, pain, itching, and local warmth of the affected eyelid, were evaluated using 10-cm visual analog scales (VASs) [12, 13]. Briefly, the item was given a score of 0 to 10 along a continuous 10-cm line, where 0 indicated the absence of symptoms and 10 indicated symptoms of the strongest intensity.

In the present study, we used a high-resolution digital camera system (Robo Skin Analyzer CS 50, NIIC Co. Ltd., Tokyo, Japan) to obtain digital images and evaluate postoperative edema [1]. The images, which were captured under highly uniform brightness [4], were analyzed using the Clinical Suite 2.1 imaging software program (NIIC Co. Ltd.) and shadow mode images were prepared. This mode detects the surface asperity of the facial skin according to the intensity of the reflected light and provides color-coded images in which blue represents the lowest degree of reflection (concave-area) and red represents the highest degree of reflection (convex-area). In this study, we used five-phase color-coded images to indicate the degree of reflection (lowest to highest: blue, green, yellow, orange, and red). We evaluated the percentage of each area of color in each eyelid using the RainbowAnalyze software program (Corefront Co. Ltd., Tokyo, Japan).

The degree of swelling was also objectively evaluated by six blinded plastic and reconstructive surgery specialists at the two hospitals from patient photographs. All surgeons were blinded to the patient information and observed the patient’s photos before surgery, just after surgery, and at one, two, four, and eight weeks after surgery; swelling was then evaluated at one and eight weeks after surgery using a 10-cm VAS. Swelling was graded on a scale of 0 to 10 along a continuous 10-cm line, where 0 indicated no symptoms and 10 indicated symptoms of the highest intensity.

2.5. Follow-Up. Follow-up examinations were scheduled for one, two, four, and eight weeks after surgery in both groups. Digital images were captured before surgery and at every follow-up examination using a Robo Skin Analyzer. The VAS score was also recorded at every follow-up examination.

2.6. Statistical Analysis. The Microsoft Excel software program (Microsoft Office Standard 2010) and the Statcel 3 software add-on (OMS Publishing Inc., Tokyo, Japan) were used for all of the statistical analyses. The age and sex in the Control and Saireito groups were compared using Fisher’s exact test. The VAS scores were compared using Fisher’s exact test. The VAS scores were compared using Fisher’s exact test. The VAS scores were compared using Fisher’s exact test. The VAS scores were compared using Fisher’s exact test.
Inclusion criteria
(i) Age ≥ 20 years
(ii) Scheduled to undergo ptosis surgery

Exclusion criteria
(i) The use of oral herbal medicine within 2 weeks before surgery
(ii) Any of the following systemic diseases or conditions:
   (a) The continuous use of oral corticosteroid therapy (>5 mg/day prednisolone equivalent) or an oral immune-suppressing drug
   (b) Malignant tumor
   (c) Hepatic failure or renal failure
(iii) Judged by the investigator to be inappropriate as the study subject

| Table 2: The demographics and surgical characteristics. |
|--------------------------------------------------------|
| **Control group**                                      | **Saireito group**            |
| Eyelids                                                | 29 (n=48)                     | 20 (n=32)                     |
| Age                                                    | 73.4±7.6                      | 66.5±9.6                      |
| Sex (male:female)                                      | 14:15                         | 6:14                          |
| History of ptosis surgery                              |                               |                               |
| Absence                                                | 23                            | 18                            |
| Presence                                               | 4                             | 0                             |
| Unknown                                                | 2                             | 2                             |
| Comorbidities                                          |                               |                               |
| High blood pressure (n=5)                              |                               |                               |
| Diabetes (n=1)                                         |                               |                               |
| Cataract (n=1)                                         |                               |                               |
| Chalazion (n=1)                                        |                               |                               |
| Meningioma (n=1)                                       |                               |                               |
| Prostatic hypertrophy (n=1)                            |                               |                               |
| Atrial fibrillation (n=1)                              |                               |                               |
| Heart disease (n=1)                                    |                               |                               |
| Diabetes (n=2)                                         |                               |                               |
| Glaucoma (n=1)                                         |                               |                               |
| Rheumatoid arthritis (n=1)                            |                               |                               |
| Diabetic retinopathy (n=1)                             |                               |                               |
| Bronchial asthma (n=1)                                 |                               |                               |
| Hyperlipidemia (n=1)                                   |                               |                               |
| Reflux esophagitis (n=1)                               |                               |                               |
| Dry eye (n=1)                                          |                               |                               |
| Cataract (n=1)                                         |                               |                               |
| Suspected cerebral infarction (n=1)                     |                               |                               |

exact probability test. The history of ptosis and the internal use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the Control and Saireito groups were compared using a chi-squared test. The VAS scores and the percentage of the colored areas in each group were analyzed using Tukey-Kramer's multiple-comparison post hoc test. The data are presented as the mean ± SD (standard deviation). P values of <0.05 were considered to indicate statistical significance.

### 3. Results

A total of 49 patients and 80 eyelids were enrolled in the present study (Control group: 29 patients, 48 eyelids; Saireito group: 20 patients, 32 eyelids) (Figure 1). In the Saireito group, one patient chose to discontinue Saireito treatment. Another patient discontinued Saireito treatment due to diarrhea; however, the patient promptly recovered after the discontinuation of Saireito. The data related to the objective findings (digital images analyzed using Robo Skin Analyzer) of 13 eyelids of 7 patients were missing and the subjective data (VAS scales) were also missing in the Control group. Thus, the digital images of 35 eyelids of 22 patients and the VAS scores of 35 eyelids of 22 patients were analyzed in the Control group. The data related to the objective findings of 12 eyelids of 8 patients were missing and the subjective data of 3 eyelids of 2 patients were missing in the Saireito group. Thus, the digital images of 17 eyelids of 10 patients and the VAS scores of 26 eyelids of 16 patients were analyzed. The objective evaluation of swelling of eyelids for which digital images from both 1 and 8 weeks were available (42 eyelids in the Control group; 35 eyelids in the Saireito group) was performed by six surgeons.

The demographic and surgical characteristics of the whole study population are shown in Table 2. The average ages of the patients in the Control and Saireito groups were 73.4 years and 66.5 years, respectively. In the analysis of the objective findings, the average ages of the patients in the Control and Saireito groups were 74.2 years and 65.1 years, respectively. In the analysis of the subjective findings,
Enrolled subject in the control group (n=29, 48 eyelids)
- 20 patients had bilateral ptosis surgery

Enrolled subject in the Saireito administration group (n=20, 32 eyelids)
- 12 patients had bilateral ptosis surgery

Dropout (n=2, 3 eyelids)

Lack of data in objective finding (n=8, 12 eyelids)
Lack of data in subjective symptoms (n=2, 3 eyelids)

Lack of data (n=7, 13 eyelids)

Objective finding
- Control Group (n=22, 35 eyelids)
- Saireito Group (n=10, 17 eyelids)

Subjective symptoms
- Control Group (n=22, 35 eyelids)
- Saireito Group (n=16, 26 eyelids)

Figure 1: The CONSORT flow diagram.

The average ages of the patients in the Control and Saireito groups were 74.1 years and 65.2 years, respectively. There were no significant differences between the Control and Saireito groups with regard to age or sex (Fisher’s exact probability test) or the history of ptosis and the internal use of NSAIDs (chi-squared test) in either the whole study population or the analysis groups of the objective findings and the subjective findings.

The time course of representative cases from the Control and the Saireito groups is shown in Figures 2(a) and 2(b), respectively. The representative patient of the Control group showed severe bilateral eyelid edema at 1 week after surgery and mild-to-moderate edema persisted from 4 to 8 weeks after surgery. On the other hand, the patient in the Saireito group developed severe edema at 1 week; however, the edema was mild at 2 weeks and had almost completely regressed at 4 weeks.

The results of the analysis of the subjective VAS scores are summarized in Figure 3. The VAS score for swelling decreased with time in both the Control and Saireito groups (Figure 3(a)). Swelling was still present at 8 weeks in the Control group and the swelling had completely disappeared at 8 weeks in the Saireito group. Furthermore, pain had completely disappeared at 4 weeks after surgery in the Saireito group, while some pain was observed in the Control group (Figure 3(b)). The VAS score for itching decreased with time in both the Control and Saireito groups. Curiously, however, the score of the Saireito group was higher than that of the Control group (Figure 3(c)). The VAS for local warmth did not differ between the two groups to a statistically significant extent (Figure 3(d)).

Next, we evaluated the time course of the changes in each color area in the color-coded images of the Control group to determine an objective method for evaluating swelling. We evaluated color-coded images that were captured with the eyelids closed because the eyelid area was too small to evaluate when the eyelids were open. No significant differences were observed in the red, orange, yellow, or green colors; however, the blue area at 1 week after surgery was significantly increased in comparison to that in the Control group.
The time course of representative cases in the Control group (a) and the Saireito group (b) shows the percentage of the blue area in each eyelid after surgery. Color-coded images with the patient’s eyes closed are shown at the bottom. The red line indicates the evaluated eyelid area. The percentage indicates the percentage of the blue area in each eyelid.

In the present study, we evaluated postoperative edema after ptosis surgery using the subjective patient-assessed VAS scores, objective surgeon-assessed VAS scores, and the computer-based analysis of images captured using a digital camera. Ptosis surgery is a basic operation. The plastic and reconstructive surgery specialists in our hospital used the same procedure when treating patients with ptosis.

Postoperative edema of the head and neck region has been evaluated according to the thickness of the soft tissue measured by ultrasound, cone beam computer tomography, and magnetic resonance imaging [16–18]. However, these methods are time-consuming for postoperative outpatients. The three-dimensional evaluation of the postoperative swelling using a 3D Digitizer is another method [19, 20]; however, the eyelids should not be exposed to laser light, as it may cause visual impairment. Our analysis of the Control group indicated that postoperative edema persisted—to some extent—at 8 weeks after surgery. We performed a computer-based analysis of images captured using a digital camera to evaluate edema because it was rapid and noninvasive method. We initially expected the red or orange area to

4. Discussion

Persistent postoperative edema is a common complication after ptosis surgery; however, an objective method for evaluating edema following eyelid ptosis surgery has not been established and no methods for objectively evaluating its duration have been reported. Studies using 3D imaging systems to evaluate persistence of postoperative edema following orthognathic surgery have revealed that 10–20 percent of primary edema remained at 3 months after surgery and that primary edema had almost disappeared at 6 months after surgery [14, 15].
increase after surgery because the edematous area is brightly reflected and is indicated by red or orange after surgery. Unexpectedly, however, these areas did not increase and the blue color area significantly increased. This was probably because the eyelid fold is sutured and fixed to the tarsus and is largely depressed in the edematous eyelid after ptosis surgery (Figure 4). The most severe edema was observed at 1 week; the subjective VAS scores indicated its gradual improvement. The depressed blue area changed to reflect the degree of edema in the same way. Thus, our image analysis reflected the state
The percentage of color-coded eyelid area (%)

Figure 4: The time course of each color-coded eyelid area in the Control group. The percentages of each color-coded area at preoperation and at 1, 2, 4, and 8 weeks after surgery are shown. The only significant difference that was observed was in the blue color area in the preoperation image and the image from 1 week after surgery (p < 0.05). *p < 0.05.

The blue color eyelid area (%)

Figure 5: The blue color eyelid area in the Control and Saireito groups. In the Control group, the blue area was significantly increased at 1 week (p < 0.05). In the Saireito group, no significant differences were observed during the study period. *p < 0.05.

Weeks after operation

Objective swelling VAS scores (cm)

Figure 6: The VAS scores for objective swelling. In both groups, the scores at 8 weeks were significantly decreased in comparison to the scores at 1 week (p<0.01). **p<0.01.

weeks in the Control group. The scores revealed that little or no edema occurred in the Saireito group at 8 weeks. The blue area increased in the Control group at 1 week; in contrast, no significant change in the blue area in the Saireito group was observed during the study period. These results suggest that the administration of Saireito might reduce the incidence of postoperative edema to some extent and that it had almost eliminated postoperative edema at 8 weeks. The only adverse event observed in this study was mild diarrhea; no severe adverse events occurred in association with the administration of Saireito [5, 8–10].

With regard to other anti-inflammatory drugs, steroids can be administrated once or for a few days after surgery and have been reported to reduce edema within several days [20, 21]. The administration of NSAIDs for several months after surgery may cause gastrointestinal ulceration; thus, it is not implemented in clinical practice [22]. Hilotherapy is a novel cooling method that is used to reduce perioperative pain and swelling in facial surgery; however, this method can only be used for a few days after surgery [12]. It is suggested that the safety of Saireito might be superior to these conventional therapies when it is administered for a number of weeks.

This study was a preliminary and nonrandomized study; therefore, the randomized and placebo-controlled study will be needed in the next step to show the efficacy of Saireito clearly.

5. Conclusion

Saireito, a traditional Japanese herbal medicine, seemed to be effective for reducing postoperative edema after acquired ptosis surgery and had almost eliminated postoperative edema at 8 weeks after surgery.
Disclosures

This work was presented at the 25th Research Council Meeting of Japan Society of Plastic and Reconstructive Surgery.

Conflicts of Interest

The authors have no financial relationship with the manufacturer of Saireito.

References

[1] S. Yadegari, “Approach to a patient with blepharoptosis,” Neurological Sciences, vol. 37, no. 10, pp. 1589–1596, 2016.
[2] G. J. Lelli Jr. and R. D. Lisman, “Blepharoplasty complications,” Plastic and Reconstructive Surgery, vol. 125, no. 3, pp. 1007–1017, 2010.
[3] S. J. Pacella and M. A. Codner, “Minor complications after blepharoplasty: dry eyes, chemosis, granulomas, ptosis, and scleral show,” Plastic and Reconstructive Surgery, vol. 125, no. 2, pp. 709–718, 2010.
[4] T. Hattori, H. Maruyama, H. Nishimura et al., “Effects of Saireito, a Japanese herbal medicine, on edema via antagonistic actions against aldosterone in anti-GBM nephritic rats,” Clinical and Experimental Nephrology, vol. 10, no. 1, pp. 13–18, 2006.
[5] S. Fukunishi, S. Nishida, K. Nakamura et al., “Co-administration of saireito enabled the withdrawal of corticosteroids in an elderly woman with autoimmune hepatitis,” Internal Medicine, vol. 55, no. 4, pp. 43–47, 2016.
[6] S. Kato, S. Hayashi, Y. Kitahara et al., “Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells,” PLoS ONE, vol. 10, no. 1, Article ID e0116213, 2015.
[7] N. Fujitsuka, K. Goto, S. Takeda, and M. Aburada, “The diuretic effect of Sairei-to is mediated by nitric oxide production in pentobarbital-anesthetized rats,” Journal of Pharmacological Sciences, vol. 94, no. 2, pp. 185–191, 2004.
[8] Y. Kishida, H. Miki, T. Nishii et al., “Therapeutic effects of Saireito (TJ-114), a traditional Japanese herbal medicine, on postoperative edema and inflammation after total hip arthroplasty,” Phytomedicine, vol. 14, no. 9, pp. 581–586, 2007.
[9] A. Nagai, Y. Shibamoto, and K. Ogawa, “Therapeutic effects of Saireito (Chai-Ling-Tang), a traditional Japanese herbal medicine, on lymphedema caused by radiotherapy: a case series study,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, 6 pages, 2013.
[10] T. Asano, Y. Fujii, N. Numao, Y. Kageyama, and K. Kihara, “The efficiency of Sairei-to for retroperitoneal fibrosis: two case reports,” Acta Urologica Japanica, vol. 52, no. 7, pp. 543–547, 2006.
[11] Q. Ye, S. J. Wang, and J. Y. Chen, “Medicinal plants for the treatment of hypertrophic scars,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 101340, 15 pages, 2015.
[12] G. E. Glass, N. Waterhouse, and K. Shakib, “Hilotraperapy for the management of perioperative pain and swelling in facial surgery: a systematic review and meta-analysis,” British Journal of Oral and Maxillofacial Surgery, vol. 54, no. 8, pp. 851–856, 2016.

Evidence-Based Complementary and Alternative Medicine